Jeremy Bender - Jan 18, 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Chief Executive Officer, Director
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Jan 18, 2022
Transactions value $
$0
Form type
4
Date filed
1/20/2022, 06:29 PM
Previous filing
May 26, 2021
Next filing
Jul 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Stock Option (right to buy Common Stock) Award $0 +397K $0.00 397K Jan 18, 2022 Common Stock 397K $14.26 Direct F1
transaction DAWN Restricted Stock Units Award $0 +57K $0.00 57K Jan 18, 2022 Common Stock 57K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F3 The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date.